Medifast (LTS:0K05) Cyclically Adjusted PS Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K05 Medifast Inc LTS:0K05
63 GF Score
Price $9.85
GF Value $8.57
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medifast Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medifast  (LTS:0K05) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medifast Cyclically Adjusted PS Ratio Related Terms


Medifast Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Medifast's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medifast Cyclically Adjusted PS Ratio Chart

Medifast Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.27 1.82 0.93 0.23 0.13

Medifast Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.17 0.13 0.13 0.00

LTS:0K05 vs RGS, CLIK, EVTK: Cyclically Adjusted PS Ratio Comparison

For the Personal Services subindustry, Medifast's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medifast Cyclically Adjusted PS Ratio vs Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, Medifast's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medifast's Cyclically Adjusted PS Ratio falls into.


LTS:0K05
63GF Score
Medifast Inc LTS:0K05
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medifast Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medifast's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Medifast's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.86/333.9520*333.9520
=6.860

Current CPI (Jun. 2026) = 333.9520.

Medifast Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.740 241.428 7.940
201612 5.200 241.432 7.193
201703 5.881 243.801 8.056
201706 6.281 244.955 8.563
201709 6.383 246.819 8.636
201712 6.413 246.524 8.687
201803 8.122 249.554 10.869
201806 9.637 251.989 12.772
201809 11.510 252.439 15.227
201812 12.174 251.233 16.182
201903 13.552 254.202 17.804
201906 15.314 256.143 19.966
201909 15.753 256.759 20.489
201912 14.284 256.974 18.563
202003 15.093 258.115 19.527
202006 18.611 257.797 24.109
202009 22.895 260.280 29.375
202012 22.299 260.474 28.589
202103 28.673 264.877 36.150
202106 33.242 271.696 40.859
202109 35.078 274.310 42.705
202112 32.205 278.802 38.575
202203 35.882 287.504 41.679
202206 39.644 296.311 44.680
202209 35.356 296.808 39.781
202212 30.667 296.797 34.506
202303 32.020 301.836 35.427
202306 27.131 305.109 29.696
202309 21.574 307.789 23.408
202312 17.510 306.746 19.063
202403 15.946 312.332 17.050
202406 15.412 314.175 16.382
202409 12.776 315.301 13.532
202412 10.843 315.605 11.473
202503 10.571 319.799 11.039
202506 9.544 322.561 9.881
202509 8.135 324.800 8.364
202512 6.831 324.054 7.040
202603 6.909 330.213 6.987
202606 6.860 333.952 6.860

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Medifast (LTS:0K05) Overvalued in 2026?

Based on GuruFocus' analysis, Medifast stock appears to be overvalued. The current stock price of $9.85 is trading 14.9% above its estimated GF Value™ of $8.57. GuruFocus considers Medifast to be Modestly Overvalued.

Key valuation signals for LTS:0K05:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $8.57 vs. price of $9.85 (14.9% above fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the LTS:0K05 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medifast Business Description

Other Exchanges MED:USAMDF:Germany
Address 100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
63GF Score

Get the complete analysis for LTS:0K05

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.85
Price
$8.57
GF Value